Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Gets Taiwan FDA Approval for Liquid Handling Platform

NEW YORK (GenomeWeb) – Vela Diagnostics said on Friday that the Sentosa SX101 instrument has been approved by the Taiwan Food and Drug Agency for in vitro diagnostic use.

The Sentosa SX101 is a multi-purpose liquid handling platform that can process 21 separate sample types. It features open channel capabilities for automated sample extraction, PCR setup, next-generation sequencing library preparation, and Sanger sequencing cleanup. The platform is validated for use with Vela's automated and integrated PCR and NGS workflow.

With the approval, Vela Diagnostics said it plans to enter the IVD market and expand its approved portfolio in Taiwan.

In November, Singapore-based Vela said that its Sentosa SX Cell-Free DNA Kit for use on the SX101 platform garnered CE marking for IVD use.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.